Shares of Novartis AG (NYSE:NVS) have been given an average recommendation of “Hold” by the seventeen brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $83.19.
A number of equities research analysts have commented on NVS shares. Zacks Investment Research raised Novartis from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Leerink Swann raised their target price on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a report on Tuesday, October 31st. Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Finally, Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th.
Novartis (NYSE NVS) traded up $1.83 during trading on Wednesday, reaching $85.43. The company’s stock had a trading volume of 1,374,388 shares, compared to its average volume of 1,721,517. Novartis has a 12 month low of $72.67 and a 12 month high of $94.19. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $221,650.00, a P/E ratio of 26.25, a P/E/G ratio of 1.95 and a beta of 0.74.
Large investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new position in shares of Novartis during the 2nd quarter worth $241,000. Bartlett & Co. LLC raised its stake in shares of Novartis by 1.6% during the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after buying an additional 7,249 shares during the last quarter. Capital Bank & Trust Co raised its stake in shares of Novartis by 5.5% during the 3rd quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after buying an additional 7,201 shares during the last quarter. Atlantic Trust Group LLC raised its stake in shares of Novartis by 54.2% during the 3rd quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after buying an additional 25,452 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of Novartis during the 3rd quarter worth $1,245,000. 11.06% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/14/novartis-ag-nvs-given-average-recommendation-of-hold-by-brokerages.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.